Psychotic and severe behavioural reactions with vigabatrin: A review

Acta Neurologica Scandinavica

Volumn 93, Issue 1, 1996, Pages 1-8

  Ferrie, C D ^a,b   Robinson, R O ^a   Panayiotopoulos, C P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Antiepileptic drug; Epilepsy; Vigabatrin, behavioural reaction

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN;

ADOLESCENT; ADULT; BEHAVIOR DISORDER; CHILD; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PSYCHOSIS; REVIEW; SEIZURE;

EID: 0030028989     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb00161.x     Document Type: Review

References (73)

1. SANDER JWAS, HART YM. Vigabatrin and behaviour disturbances. Lancet 1990: 335: 57.
2. DAM M. Vigabatrin and behaviour disturbances. Lancet 1990: 335: 605.
3. BETTS T, THOMAS L. Vigabatrin and behaviour disturbances. Lancet 1990: 335: 605-606.
4. JOHNS SJ. Vigabatrin and behaviour disturbances. Lancet 1990: 335: 606.
5. BRODIE MJ, MCKEE PJW. Vigabatrin and psychosis. Lancet 1990: 335: 1279.
6. RING HA, REYNOLDS EH. Vigabatrin and psychosis. Lancet 1990: 335: 970.
7. ROBINSON MK, RICHENS A, OXLEY R. Vigabatrin and behaviour disturbances. Lancet 1990: 335: 504.
8. SANDER JWAS, HART YM, TRIMBLE MR, SCHORVON SD. Vigabatrin and psychosis. J Neurol Neurosurg Psych 1991: 54: 435-439.
9. STAPLES CI, KING MA, BOYLE RS. Acute psychosis after withdrawal of vigabatrin. Med J Aust 1992: 156: 291.
10. STORES G. Behavioural effects of anti-epileptic drugs. Dev Med Child Neurol 1975: 17: 647-658.
11. TRIMBLE MR. The psychoses of epilepsy. New York: Raven Press 1991.
12. AICARDI J. Psychiatric and behavioural problems in epilepsy, hydrocephalus and cerebral palsy. In: AICARDI J. Diseases of the nervous system in childhood. Oxford: Mac Keith Press, 1992: 1357-1361.
13. ZIELINSKI JJ. Epidemiology and medical-social problems of epilepsy in Warsaw. Psychoneurological Institute, Warsaw, Poland. Final report, res prog no 19-P-58325-F-01, pp. 1-237.
14. GUDMUNDSSON G. Epilepsy in Iceland: a clinical and epidemiological investigation. Acta Neurol Scand 1966: 43 (suppl 25): 1-124.
15. AIRD RB, MASLAND RL, WOODBURY DM. The epilepsies: a critical review. New York: Raven Press, 1984.
16. DAVISON K, HASSANYEH F. Psychiatric disorders. In: DAVIES DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1991, 601-642.
17. SCHMIDT D. Adverse effects of antiepileptic drugs. New York: Raven Press, 1982.
18. OUNSTED C. The hyperkinetic syndrome in epileptic children. Lancet 1955(ii): 303-311.
19. BOOKER HE. Primidone toxicity. In: WOODBURY DM, PENRY JK, SCHMIDT RP, ed. Anti-epileptic drugs. New York: Raven Press, 1972.
20. MCDANAL CE, BOLMAN WM. Delayed idiosyncratic psychosis with diphenylhydantoin. JAMA 1975: 231: 1063.
21. MATHEW G. Psychiatric symptoms associated with carbamazepine. Br Med J 1988: 296: 1071.
22. GARDNER DL, COWDRY RW. Development of melancholia during carbamazepine treatment in borderline personality disorder. J Clin Psychopharmacol 1986: 6: 236-239.
23. CHADWICK DW. Concentration-effect relationships of valproic acid. Clinical Pharmacokinet 1985: 10: 155-163.
24. LAUTIN A, ANGRIST B, STANLEY M, GERSHON S, HECKL K, KAROBATH M. Sodium valproate in schizophrenia: some biochemical correlates. Br J Psychiatry 1980: 137: 240-244.
25. WHITE MC, SILVERMAN JJ, HARBISON JW. Psychosis associated with clonazepam therapy for blethorospasm. J Nerv Ment Dis 1982: 170: 117-119.
26. FRANKS RD, RICHTER J. Schizophrenia-like psychosis associated with anticonvulsant toxicity. Am J Psychiatry 1979: 136: 973-974.
27. SAVARD G, ANDERMANN F, OLIVIER A, REMILLARD GM. Postictal psychosis after partial complex seizures: a multiple cases study. Epilespia 1991: 32: 225-231.
28. GRAM L, KLOSTERSKOV P, DAM M. Gamma-vinyl GABA: a double blind placebo-controlled study in partial epilepsy. Ann Neurol 1985: 17: 262-266.
29. LOISEAU P, HARDENGERG JP, PESTRE M, GUYOT M, SCHECHTER, TELL GP. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986: 27: 115-120.
30. TARTARA A, MANNI R, GALIMBERTI CA, HARDENBERG J, ORWIN J, PERUCCA E. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. Epilepsia 1986: 27: 717-723.
31. RÉMY C, FAVEL P, TELL G, HARDENBERG J, SCHECHTER PJ. Etude en double aveugle contre placebo en permutations croisées du vigabatrin dans l'épilepsie de l'adulte résistant a la thérapeutique. Boll Lega Ital Epil 1986: 54/55: 241-243.
32. RIMMER EM, RICHENS E. Double blind study of γ-vinyl GABA in patients with refractory epilepsy. Lancet Jan 28, 1984: 189-190.
33. TASSINARI CA, MICHELUCCI R, AMBROSETTO G, SALVI F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 1987: 44: 307-310.
34. BROWNE TR, MATTSON RH, PENRY JK et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987: 7: 184-189.
35. SIVENIUS MRJ, YLINEN A, MURROS K, MATILAINEN R, RIEKKINEN P. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia 1987: 28: 688-692.
36. REYNOLDS EH, RING HA, FARR IN, HELLER AJ, ELWES RDC. Open, double-blind and long term study of vigabatrin in chronic epilepsy. Epilepsia 1991: 32: 530-538.
37. AINLEY P, ANDERSON D, BANKS G et al. Cognitive performance in patients with uncontrolled seizures during a double blind placebo controlled cross-over study of two doses of vigabatrin in patients suffering from drug resistant seizures. Epilepsia 1993: 34 (suppl 2): 118.
38. MUMFORD JP, CANNON DJ. Vigabatrin. Epilepsia 1994: 35 (suppl 5): 25-28.
39. MUMFORD JP. Vigabatrin (Sabril): the strategy for preclinical and clinical evaluation. Boll Lega Ital Epil 1994: 86/87: 19-23.
40. BUCHANAN N. Vigabatrin in drug resistant epilepsy. Med J Aust 1993: 159-135.
41. LHOIR A. Vigabatrin in unsatisfactorily controlled epilepsy: Belgian clinical experience. Epilepsia 1993: 34 (suppl 2): 118.
42. SAMPAIO MJ, SOUSA L, SANTANA I, KEATING J. Clinical experience with vigabatrin as an add-on therapy in drug resistant partial seizures at University Hospital of Coimbra. Epilepsia 1993: 34 (suppl 2): 117.
43. ALDENKAMP AP, VERMEULEN J, MULDER OG et al. γ-Vinyl GABA (vigabatrin) and mood disturbances. Epilepsia 1994: 35: 999-1004.
44. HERRANZ JL, ARTEAGA R, FARR IN, VALDIZAN E, BEAUMONT D, ARMIJO JA. Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurol 1991: 6 (suppl 2): 45-51.
45. LIVINGSTON JH, BEAUMONT O, ARZIMANOGLOU A, AICARDI J. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol 1989: 27: 109-112.
46. DULAC O, CHIRON C, LUNA D, CUSMAI R, PAJOT N, BEAUMONT D, MONDRAGON S. Vigabatrin in childhood epilepsy. J Child Neurol 1991: 6 (suppl 2): 30-37.
47. ULDALL P, ALVING J, GRAM L, BECK S. Vigabatrin in pediatric epilepsy - an open study. J Child Neurol 1991: 6 (suppl 2): 38-44.
48. COPPOLA G, BOVE RM, ALTIERI A, PASCOTTO A. Vigabatrin in children with refractory epilepsy. Epilepsia 1993: 34 (suppl 2): 119.
49. DELLA BERNARDINO B et al. Efficacy and tolerability of vigabatrin in children with refractory epilepsy: a scaling-up dose response study. Epilepsia 1993: 34 (suppl 2): 121.
50. FOIS A, DI BARTOLO RM, DI MARCO V, MOSTARDINI R. Vigabatrin treatment in children. Epilepsia 1993: 34 (suppl 2): 119.
51. GRAM L, SABERS A, DULAC O. Treatment of pediatric epilepsies with γ-vinyl GABA (vigabatrin). Epilepsia 1992: 33 (suppl 5): 26-29.
52. RAVNIK IM, PRIMEC ZR, ŽUFANC̄IC̄ Netal Effect of vigabatrin in paediatric and adolescent epilepsy. Epilepsia 1993: 34 (suppl 2): 117.
53. RENIER WO, BRAAN W, ARNOLDUSSEN W, OEI T. Vigabatrin as add-on medication in children with therapy resistant epilepsy. Epilepsia 1993: 34 (suppl 2): 121.
54. BETTS T. Management of psychotic reactions related to use of vigabatrin. Epilepsia 1993: 34 (suppl 2): 118.
55. REMY C, BEAUMONT D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989: 27: 125-129.
56. TARTARA A, MANNI E, GALIMBERTI CA, et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992: 86: 247-251.
57. BROWNE TR, MATTSON RH, PENRY JK, et al. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol 1989: 27 (suppl 1): 95-100.
58. BOWERY N, RICHARDS DA, LEMOS T, WHITTON PS. GABA transmission in absence epilepsy. In: DUNCAN JS, PANAYIOTOFOULOS CP, ed. Typical absences and related epileptic syndromes. Edinburgh: Churchill Livingstone, 1995, 51-58.
59. FUNGELD EW, BENTER L, ZIMMERMANN P. Activating effects of gamma-vinyl GABA in anergic chronic schizophrenics. 3rd. World Congress Biol Psychiatr. Stockholm 1981 (Abstract F145).
60. LAMBERT PA, CHABANNES JP, CANTINIAUX P, SCHECHTER PJ, TELL GP. Effets du gamma-vinyl GABA per os dans cinq cas de schizophrénia hébéphréno-catatonique. Encephale 1983: IX: 145-149.
61. TAMMINGA CA, THAKER GK, FERRARO TN, HARE TA. GABA agonist treatment improves tardive dyskinesia. Lancet 1983: vol ii: 97-98.
62. KORSGAARD S, CASEY DE, GERLACH J. Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res 1983: 8: 261-269.
63. DANNION JM, SINGER L, TELL G, SCHECHTER P. Gamma-vinyl-GABA et dyskinésia tardives: une étude en simple insu contre placebo. Ann Med Psychol 1984: 142: 104-110.
64. STAHL SM, THORNTON JE, SIMPSON ML, BERGER PA, NAPOLIELLO MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biol Psychiatry 1985: 20: 888-893.
65. GAIO JM, POLLAK P, HOMMEL M, PERRET J. Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia. J Neurol Neurosurg Psych 1987: 50: 1674-1678.
66. MATILAINEN R, PITKANEN A, RUUTIAINEN T, MERVAALA E, RIEKKINEN P. Vigabatrin in epilepsy in mentally retarded patients. Br J Clin Pharmacol 1989: 27 (suppl 1): 113-118.
67. PITKANEN A, YLINEN A, MATILAINEN R et al. Long-term antiepileptic efficacy of vigabatrin in drug-refractory epilepsy in mentally retarded patients: a 5 year follow-up study. Arch Neurol 1993: 50: 24-29.
68. MATSUO F, BERGEN D, FAUGHT E, MESSENHEIMER JA, DREN AT, RUDD GD, LINEBERRY CG. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993: 43: 2284-2291.
69. US Gabapentin Study Group. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993: 43: 2292-2298.
70. SIEVENIUS J, KALVIAINEN R, YLINEN A, RIEKKINEN P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991: 32: 539-542.
71. LORTIE A, CHIRON C, MUMFORD J, DULAC O. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993: 43 (suppl 5): 24-27.
72. MELDRUM B. GABA and acute psychosis. Psychol Med 1982: 12: 1-5.
73. RING HA, TRIMBLE MR, COSTA DC, GEORGE MS, VERHOEFF P, ELL PJ. Effect of vigabatrin on striatal dopamine receptors; evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psych 1992: 55: 758-761.